Last reviewed · How we verify
Anlotinib plus Pemetrexed
Anlotinib inhibits multiple receptor tyrosine kinases to block tumor angiogenesis, while pemetrexed inhibits folate-dependent enzymes to disrupt DNA synthesis in cancer cells.
Anlotinib inhibits multiple receptor tyrosine kinases to block tumor angiogenesis, while pemetrexed inhibits folate-dependent enzymes to disrupt DNA synthesis in cancer cells. Used for Non-small cell lung cancer (NSCLC), likely advanced or metastatic stages.
At a glance
| Generic name | Anlotinib plus Pemetrexed |
|---|---|
| Sponsor | Henan Provincial People's Hospital |
| Drug class | Multi-target tyrosine kinase inhibitor plus antifolate antimetabolite |
| Target | VEGFR, FGFR, RET, c-Kit (anlotinib); thymidylate synthase, DHFR, GARFT (pemetrexed) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Anlotinib is a multi-target tyrosine kinase inhibitor that suppresses VEGFR, FGFR, and other kinases involved in tumor blood vessel formation and growth. Pemetrexed is an antifolate agent that inhibits thymidylate synthase and other folate-dependent enzymes, disrupting nucleotide synthesis and inducing apoptosis. The combination leverages complementary mechanisms: antiangiogenic activity plus direct cytotoxic chemotherapy.
Approved indications
- Non-small cell lung cancer (NSCLC), likely advanced or metastatic stages
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea/vomiting
- Fatigue
- Hypertension
- Hand-foot skin reaction
Key clinical trials
- Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC (PHASE2)
- First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma (PHASE2)
- Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC (PHASE2)
- A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer (PHASE3)
- Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI (PHASE2)
- Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer (PHASE1)
- Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors) (PHASE2)
- A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anlotinib plus Pemetrexed CI brief — competitive landscape report
- Anlotinib plus Pemetrexed updates RSS · CI watch RSS
- Henan Provincial People's Hospital portfolio CI